title icon

Presentations & Publications

2017 AACR Poster: Tumor Suppressor TUSC2 Immunogene Therapy is Synergistic with Anti-PD1 in Syngeneic Mouse Models of Lung Cancer

TUSC2 (formerly known as FUS1, the active anti-cancer agent in OncoprexTM) in combination with PD-1 checkpoint inhibition has a significantly greater anti-tumor effect in lung cancer than either agent alone. The research also shows that TUSC2 in combination with PD-1 blockade has synergistic activity in upregulating natural killer (NK) cells, correlated with prolonged survival in mice.

TUSC2 is a tumor suppressor gene that is lacking in cancer cells of many different cancer types, including non-small cell lung cancer (NSCLC). It is a pan-kinase inhibitor that has been shown in-vivo to affect cell proliferation and programmed cell death. PD-1 is a protein found on certain types of T cells, which are part of the immune system. Because PD-1 prevents T cells from attacking other cells, including in some cases cancer cells, inhibiting PD-1 can facilitate the immune response to cancer.

The research was presented at the 2017 Annual Meeting of the American Association of Cancer Research in Washington, D.C.

Download a PDF

Phase I Clinical Trial of Systemically Administered TUSC2(FUS1)-Nanoparticles Mediating Functional Gene Transfer in Humans

Tumor suppressor gene TUSC2/FUS1 (TUSC2) is frequently inactivated early in lung cancer development. TUSC2 mediates apoptosis in cancer cells but not normal cells by upregulation of the intrinsic apoptotic pathway. No drug strategies currently exist targeting loss-of–function genetic abnormalities. We report the first in-human systemic gene therapy clinical trial of tumor suppressor gene TUSC2.

Full publication can be found here.

2012 AACR Poster: Synergistic inhibition of tumor growth and overcoming resistance in Lung Cancer by combining novel dual-targeting DNA-alkylating/HDAC inhibitor with Tumor Suppressor NPRL2- and p53-nanoparticles

DNA alkylating agents such as platinum and nitrogen mustard are effective cancer chemotherapeutics. They kill proliferating tumor cells by inducing high levels of DNA damage leading to cell-cycle arrest and cell death. However, their highly toxic side effects and the common drug resistance exhibited in tumors limit their anticancer efficacy and clinical benefits. Here we describe a novel anticancer therapeutic strategy using a new class of rationally designed dual DNA alkylating/HDAC inhibitors combined with nanovesicle-mediated gene therapy targeting the DNA damage/repair pathway in human NSCLC and SCLC cells.

2012 AACR Poster: Phase I Clinical Study of Synergistic Antitumor Activity of MK2206 and TUSC2/FUS1-nanoparticle in NSCLC

TUSC2, a novel tumor suppressor gene in the human chromosome 3p21.3 region, is deleted in many cancers. A phase I clinical trial assessing TUSC2-mediated molecular therapy has reported antitumor activity in lung cancer patients. Previous studies showed that TUSC2 regulates the activation of multiple oncogenic kinases. MK2206 is a highly selective non-ATP-competitive allosteric inhibitor of AKT currently being evaluated in early-phase clinical trials for treatment of patients with lung cancer.

2011 AACR Poster: Phase I Clinical Study of Systemic TUSC2 Nanoparticle Therapy (Oncoprex®) in Stage IV Lung Cancer Patients

A poster describing a phase I clinical trial investigating Oncoprex® (intravenous TUSC2 nanovesicles) used a single agent in recurrent, metastatic lung cancer patients. The dose escalation clinical trial was conducted at The University of Texas MD Anderson Cancer Center. The poster was presented at the 2011 Annual Meeting of the American Association for Cancer Research (AACR) and received a Highly Rated Paper award from AACR.

2011 AACR Abstract: Phase I Clinical Study of Systemic TUSC2 Nanoparticle Therapy (Oncoprex®) in Stage IV Lung Cancer Patients

An abstract describing a phase I clinical trial investigating Oncoprex® (intravenous TUSC2 nanovesicles) used a single agent in recurrent, metastatic lung cancer patients. The dose escalation clinical trial was conducted at The University of Texas MD Anderson Cancer Center. The abstract was published in the Proceedings of the 2011 Annual Meeting of the American Association for Cancer Research (AACR) and was awarded a Highly Rated Paper by AACR.

Bibliography

A bibliography of selected publications describing technologies from Genprex.

 

<!– Facebook Pixel Code –>
<script>
!function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function(){n.callMethod?
n.callMethod.apply(n,arguments):n.queue.push(arguments)};if(!f._fbq)f._fbq=n;
n.push=n;n.loaded=!0;n.version=’2.0′;n.queue=[];t=b.createElement(e);t.async=!0;
t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window,
document,’script’,’https://connect.facebook.net/en_US/fbevents.js’);
fbq(‘init’, ‘1840809086181892’); // Insert your pixel ID here.
fbq(‘track’, ‘PageView’);
</script>
<noscript><img height=”1″ width=”1″ style=”display:none”
src=”https://www.facebook.com/tr?id=1840809086181892&ev=PageView&noscript=1″
/></noscript>
<!– DO NOT MODIFY –>
<!– End Facebook Pixel Code –>